NGNE
Neurogene Inc.
1W: -11.4%
1M: +2.3%
3M: -0.5%
YTD: -5.5%
1Y: +23.5%
3Y: +53.6%
5Y: -92.0%
$19.05
-0.14 (-0.73%)
After Hours: $20.70 (+1.65, +8.66%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$295.1M
52W Range6.875-37.266
Volume249,728
Avg Volume162,489
Beta1.69
Dividend—
Analyst Ratings
Company Info
CEORachel L. McMinn
Employees107
SectorHealthcare
IndustryBiotechnology
IPO Date2014-03-07
Websiteneurogene.com
535 W 24th Street
New York City, NY 10011
US
New York City, NY 10011
US
(877) 237-5020
About Neurogene Inc.
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Latest News
Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Consensus Price Target from Analysts
Yatsen Holding, Delta Air Lines, United Airlines And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Neurogene Stock Soars On FDA Breakthrough Tag For Rett Gene Therapy
Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Cobb Stuart | S-Sale | 3,991 | $20.41 | 2026-03-13 |
| Cobb Stuart | S-Sale | 2,658 | $21.34 | 2026-03-13 |
| Cobb Stuart | S-Sale | 148 | $22.08 | 2026-03-13 |
| Cvijic Christine Mik | S-Sale | 2,387 | $20.42 | 2026-03-13 |
| Cvijic Christine Mik | S-Sale | 1,395 | $21.25 | 2026-03-13 |